Profit and Loss Results Results Snapshot
Figures in Cr
Consolidated - Profit And Loss Results
Mar'25
Mar'24
Mar'23
No of Months
12
12
12
Operating Income
313.00
203.00
182.00
Less :Inter divisional transfers
0.00
0.00
0.00
Less: Excise
0.00
0.00
0.00
Net Sales
313.00
203.00
182.00
Expenditure (Ex Depriciation)
Stock Adjustments
24.00
-28.00
-4.00
Raw Materials Consumed
121.00
121.00
92.00
Power & Fuel Cost
1.00
0.00
0.00
Employee Cost
30.00
23.00
23.00
Operating Expenses
15.00
17.00
10.00
General and Administration Expenses
-1.00
-1.00
-1.00
Selling and Distribution Expenses
4.00
5.00
8.00
Cost of Software developments
0.00
0.00
0.00
Miscellaneous Expenses
8.00
3.00
2.00
Expenses Capitalised
0.00
0.00
0.00
Total Expenditure
239.00
165.00
148.00
Operating Profit (PBDIT) excl Other Income
74.00
38.00
33.00
Other Income
8.00
2.00
2.00
Operating Profit (PBDIT)
83.00
40.00
35.00
Interest
14.00
6.00
3.00
Profit before Depriciation and Tax
68.00
34.00
31.00
Depreciation
7.00
3.00
2.00
Profit Before Taxation & Exceptional Items
61.00
30.00
29.00
Exceptional Income / Expenses
0.00
0.00
0.00
Profit Before Tax
44.00
30.00
29.00
Provision for Tax
19.00
8.00
8.00
Profit After Tax
24.00
21.00
21.00
Extraordinary Items
0.00
0.00
0.00
Adj to Profit After Tax
0.00
0.00
0.00
Profit Balance B/F
158.00
124.00
92.00
Profit Available for appropriations
187.00
158.00
124.00
Appropriations
187.00
158.00
124.00
Equity Dividend (%)
0.00%
0.00%
0.00%
Earnings Per Share
28.63
21.87
20.38
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is 54.08% vs 11.44% in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is 95.70% vs 12.77% in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 133.81% vs 64.60% in Mar 2024
Profit After Tax
YoY Growth in year ended Mar 2025 is 13.27% vs 1.21% in Mar 2024
Compare Profit and Loss Results of Q-Line Biotech
Figures in Cr
consolidated - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
313.00
0
313.00
0%
Less :Inter divisional transfers
0.00
0
0.00
0%
Less: Excise
0.00
0
0.00
0%
Net Sales
313.00
0
313.00
0%
Expenditure (Ex Depriciation)
Stock Adjustments
24.00
0
24.00
0%
Raw Materials Consumed
121.00
0
121.00
0%
Power & Fuel Cost
1.00
0
1.00
0%
Employee Cost
30.00
0
30.00
0%
Operating Expenses
15.00
0
15.00
0%
General and Administration Expenses
-1.00
0
-1.00
0%
Selling and Distribution Expenses
4.00
0
4.00
0%
Cost of Software developments
0.00
0
0.00
0%
Miscellaneous Expenses
8.00
0
8.00
0%
Expenses Capitalised
0.00
0
0.00
0%
Total Expenditure
239.00
0
239.00
0%
Operating Profit (PBDIT) excl Other Income
74.00
0.00
74.00
0%
Other Income
8.00
0
8.00
0%
Operating Profit (PBDIT)
83.00
0
83.00
0%
Interest
14.00
0
14.00
0%
Profit before Depriciation and Tax
68.00
0
68.00
0%
Depreciation
7.00
0
7.00
0%
Profit Before Taxation & Exceptional Items
61.00
0
61.00
0%
Exceptional Income / Expenses
0.00
0
0.00
0%
Profit Before Tax
44.00
0
44.00
0%
Provision for Tax
19.00
0
19.00
0%
Profit After Tax
24.00
0
24.00
0%
Extraordinary Items
0.00
0
0.00
0%
Adj to Profit After Tax
0.00
0
0.00
0%
Profit Balance B/F
158.00
0
158.00
0%
Profit Available for appropriations
187.00
0
187.00
0%
Appropriations
187.00
0
187.00
0%
Equity Dividend (%)
0%
0%
0.00
Earnings Per Share
28.63
0
28.63
0%
Profit And Loss - Net Sales
Net Sales 313.78 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 54.08% vs 11.44% in Mar 2024
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 74.49 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 95.70% vs 12.77% in Mar 2024
Profit And Loss - Interest
Interest 14.81 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 133.81% vs 64.60% in Mar 2024
Profit And Loss - Profit After Tax
Profit After Tax 24.51 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 13.27% vs 1.21% in Mar 2024
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
